{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:20:20Z","timestamp":1792160420730,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-022-02466-5","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T11:10:48Z","timestamp":1669201848000},"page":"729-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cutaneous manifestations of sickle cell disease: an updated review"],"prefix":"10.1007","volume":"315","author":[{"given":"Alexander","family":"Dick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1622-1097","authenticated-orcid":false,"given":"Amor","family":"Khachemoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"2466_CR1","unstructured":"CDC (2020) Data & Statistics on Sickle Cell Disease. In: Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/NCBDDD\/sicklecell\/data.html. Accessed 2 Jan 2021"},{"key":"2466_CR2","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/nejmra1510865","volume":"376","author":"FB Piel","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC (2017) Sickle cell disease. N Engl J Med 376:1561\u20131573. https:\/\/doi.org\/10.1056\/nejmra1510865","journal-title":"N Engl J Med"},{"key":"2466_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators (2015) Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Lond Engl 385:117\u2013171. https:\/\/doi.org\/10.1016\/S0140-6736(14)61682-2","journal-title":"Lancet Lond Engl"},{"key":"2466_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3109\/03630269009046967","volume":"14","author":"DR Powars","year":"1990","unstructured":"Powars DR (1990) Sickle cell anemia and major organ failure. Hemoglobin 14:573\u2013598. https:\/\/doi.org\/10.3109\/03630269009046967","journal-title":"Hemoglobin"},{"key":"2466_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","volume":"14","author":"P Sundd","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM (2019) Pathophysiology of sickle cell disease. Annu Rev Pathol Mech Dis 14:263\u2013292. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012418-012838","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2466_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1056\/NEJM199709113371107","volume":"337","author":"HF Bunn","year":"1997","unstructured":"Bunn HF (1997) Pathogenesis and treatment of sickle cell disease. N Engl J Med 337:762\u2013769. https:\/\/doi.org\/10.1056\/NEJM199709113371107","journal-title":"N Engl J Med"},{"key":"2466_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.110.2865.543","volume":"110","author":"L Pauling","year":"1949","unstructured":"Pauling L, Itano HA (1949) Sickle cell anemia a molecular disease. Science 110:543\u2013548. https:\/\/doi.org\/10.1126\/science.110.2865.543","journal-title":"Science"},{"key":"2466_CR8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.chest.2015.12.016","volume":"149","author":"EM Novelli","year":"2016","unstructured":"Novelli EM, Gladwin MT (2016) Crises in sickle cell disease. Chest 149:1082\u20131093. https:\/\/doi.org\/10.1016\/j.chest.2015.12.016","journal-title":"Chest"},{"key":"2466_CR9","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","volume":"122","author":"D Manwani","year":"2013","unstructured":"Manwani D, Frenette PS (2013) Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 122:3892\u20133898. https:\/\/doi.org\/10.1182\/blood-2013-05-498311","journal-title":"Blood"},{"key":"2466_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13146","author":"LS Torres","year":"2022","unstructured":"Torres LS, Hidalgo A (2022) Neutrophils as drivers of vascular injury in sickle cell disease. Immunol Rev. https:\/\/doi.org\/10.1111\/imr.13146","journal-title":"Immunol Rev"},{"key":"2466_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","volume":"127","author":"D Zhang","year":"2016","unstructured":"Zhang D, Xu C, Manwani D, Frenette PS (2016) Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood 127:801\u2013809. https:\/\/doi.org\/10.1182\/blood-2015-09-618538","journal-title":"Blood"},{"key":"2466_CR12","doi-asserted-by":"crossref","unstructured":"Jones H, Morey B, Anadkat M (2013) Cutaneous manifestations of Sickle cell disease. In: ResearchGate. https:\/\/www.researchgate.net\/publication\/272880256_Cutaneous_Manifestations_of_Sickle_Cell_Disease. Accessed 2 Jan 2021","DOI":"10.4236\/ojbd.2013.33019"},{"key":"2466_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/00129334-200410000-00010","volume":"17","author":"JT Trent","year":"2004","unstructured":"Trent JT, Kirsner RS (2004) Leg ulcers in sickle cell disease. Adv Skin Wound Care 17:410\u2013416. https:\/\/doi.org\/10.1097\/00129334-200410000-00010","journal-title":"Adv Skin Wound Care"},{"key":"2466_CR14","first-page":"179","volume":"74","author":"JB Herrick","year":"2001","unstructured":"Herrick JB (2001) Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910. Yale J Biol Med 74:179\u2013184","journal-title":"Yale J Biol Med"},{"key":"2466_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/ajh.21838","volume":"85","author":"CP Minniti","year":"2010","unstructured":"Minniti CP, Eckman J, Sebastiani P et al (2010) Leg ulcers in sickle cell disease. Am J Hematol 85:831\u2013833. https:\/\/doi.org\/10.1002\/ajh.21838","journal-title":"Am J Hematol"},{"key":"2466_CR16","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood.V74.4.1403.1403","volume":"74","author":"M Koshy","year":"1989","unstructured":"Koshy M, Entsuah R, Koranda A et al (1989) Leg ulcers in patients with sickle cell disease. Blood 74:1403\u20131408","journal-title":"Blood"},{"key":"2466_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/archinte.1974.00320160184017","volume":"133","author":"GR Serjeant","year":"1974","unstructured":"Serjeant GR (1974) Leg ulceration in sickle cell anemia. Arch Intern Med 133:690. https:\/\/doi.org\/10.1001\/archinte.1974.00320160184017","journal-title":"Arch Intern Med"},{"key":"2466_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1365-2133.2007.08323.x","volume":"158","author":"M Halabi-Tawil","year":"2007","unstructured":"Halabi-Tawil M, Lionnet F, Girot R et al (2007) Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. Br J Dermatol 158:339\u2013344. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08323.x","journal-title":"Br J Dermatol"},{"key":"2466_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000338150","volume":"122","author":"AB Levine","year":"2012","unstructured":"Levine AB, Punihaole D, Levine TB (2012) Characterization of the role of nitric oxide and its clinical applications. Cardiology 122:55\u201368. https:\/\/doi.org\/10.1159\/000338150","journal-title":"Cardiology"},{"key":"2466_CR20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.biocel.2006.01.010","volume":"38","author":"AK Mack","year":"2006","unstructured":"Mack AK, Kato GJ (2006) Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol 38:1237\u20131243. https:\/\/doi.org\/10.1016\/j.biocel.2006.01.010","journal-title":"Int J Biochem Cell Biol"},{"key":"2466_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1042\/cs0920153","volume":"92","author":"JS Mohan","year":"1997","unstructured":"Mohan JS, Marshall JM, Reid HL et al (1997) Postural vasoconstriction and leg ulceration in homozygous sickle cell disease. Clin Sci Lond Engl 1979 92:153\u2013158. https:\/\/doi.org\/10.1042\/cs0920153","journal-title":"Clin Sci Lond Engl 1979"},{"key":"2466_CR22","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.hoc.2005.08.005","volume":"19","author":"GR Serjeant","year":"2005","unstructured":"Serjeant GR, Serjeant BE, Mohan JS, Clare A (2005) Leg ulceration in sickle cell disease: medieval medicine in a modern world. Hematol Oncol Clin N Am 19:943\u2013956. https:\/\/doi.org\/10.1016\/j.hoc.2005.08.005","journal-title":"Hematol Oncol Clin N Am"},{"key":"2466_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/WON.0000000000000281","volume":"43","author":"LE Edsberg","year":"2016","unstructured":"Edsberg LE, Black JM, Goldberg M et al (2016) Revised national pressure ulcer advisory panel pressure injury staging system: revised pressure injury staging system. J Wound Ostomy Cont Nurs 43:585\u2013597. https:\/\/doi.org\/10.1097\/WON.0000000000000281","journal-title":"J Wound Ostomy Cont Nurs"},{"key":"2466_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/01.asw.0000419408.37323.0c","volume":"25","author":"B Ladizinski","year":"2012","unstructured":"Ladizinski B, Bazakas A, Mistry N et al (2012) Sickle cell disease and leg ulcers. Adv Skin Wound Care 25:420\u2013428. https:\/\/doi.org\/10.1097\/01.asw.0000419408.37323.0c","journal-title":"Adv Skin Wound Care"},{"key":"2466_CR25","doi-asserted-by":"publisher","first-page":"932","DOI":"10.7326\/0003-4819-148-12-200806170-00220","volume":"148","author":"OW Brawley","year":"2008","unstructured":"Brawley OW, Cornelius LJ, Edwards LR et al (2008) National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 148:932\u2013938. https:\/\/doi.org\/10.7326\/0003-4819-148-12-200806170-00220","journal-title":"Ann Intern Med"},{"key":"2466_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s1072-7515(98)00196-3","volume":"187","author":"M Cackovic","year":"1998","unstructured":"Cackovic M, Chung C, Bolton LL, Kerstein MD (1998) Leg ulceration in the sickle cell patient. J Am Coll Surg 187:307\u2013309. https:\/\/doi.org\/10.1016\/s1072-7515(98)00196-3","journal-title":"J Am Coll Surg"},{"key":"2466_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/B978-0-323-71236-1.00029-4","volume-title":"Dermatology for the primary care provider","author":"A Grada","year":"2022","unstructured":"Grada A, Phillips T (2022) Ulcers. Dermatology for the primary care provider. Elsevier, Amsterdam, pp 310\u2013320"},{"key":"2466_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.autrev.2010.11.008","volume":"10","author":"PR Criado","year":"2011","unstructured":"Criado PR, Rivitti EA, Sotto MN, de Carvalho JF (2011) Livedoid vasculopathy as a coagulation disorder. Autoimmun Rev 10:353\u2013360. https:\/\/doi.org\/10.1016\/j.autrev.2010.11.008","journal-title":"Autoimmun Rev"},{"key":"2466_CR29","unstructured":"Majmundar VD, Kalgi B (2021) Livedoid vasculopathy. In: Nih.gov. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559037\/. Accessed 2 Jan 2021"},{"key":"2466_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.4103\/0378-6323.183635","volume":"82","author":"B Vasudevan","year":"2016","unstructured":"Vasudevan B, Neema S, Verma R (2016) Livedoid vasculopathy: A review of pathogenesis and principles of management. Indian J Dermatol Venereol Leprol 82:478. https:\/\/doi.org\/10.4103\/0378-6323.183635","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2466_CR31","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaad.2013.07.019","volume":"69","author":"A Alavi","year":"2013","unstructured":"Alavi A, Hafner J, Dutz JP et al (2013) Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. J Am Acad Dermatol 69:1033-1042.e1. https:\/\/doi.org\/10.1016\/j.jaad.2013.07.019","journal-title":"J Am Acad Dermatol"},{"key":"2466_CR32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/dad.0000000000001133","volume":"40","author":"H Reagin","year":"2018","unstructured":"Reagin H, Marks E, Weis S, Susa J (2018) Livedoid vasculopathy presenting in a patient with sickle cell disease. Am J Dermatopathol 40:682\u2013685. https:\/\/doi.org\/10.1097\/dad.0000000000001133","journal-title":"Am J Dermatopathol"},{"key":"2466_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1742-481x.2011.00882.x","volume":"9","author":"J El Khoury","year":"2011","unstructured":"El Khoury J, Taher A, Kurban M et al (2011) Livedoid vasculopathy associated with sickle cell trait: significant improvement on aspirin treatment. Int Wound J 9:344\u2013347. https:\/\/doi.org\/10.1111\/j.1742-481x.2011.00882.x","journal-title":"Int Wound J"},{"key":"2466_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0163-4453(83)90863-0","volume":"7","author":"JK Onwubalili","year":"1983","unstructured":"Onwubalili JK (1983) Sickle cell disease and infection. J Infect 7:2\u201320. https:\/\/doi.org\/10.1016\/S0163-4453(83)90863-0","journal-title":"J Infect"},{"key":"2466_CR35","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijid.2009.03.010","volume":"14","author":"C Booth","year":"2010","unstructured":"Booth C, Inusa B, Obaro SK (2010) Infection in sickle cell disease: a review. Int J Infect Dis 14:e2\u2013e12. https:\/\/doi.org\/10.1016\/j.ijid.2009.03.010","journal-title":"Int J Infect Dis"},{"key":"2466_CR36","volume-title":"Practical manual of haemoglobinopathies","author":"IE Okpala","year":"2007","unstructured":"Okpala IE (2007) Practical manual of haemoglobinopathies. John Wiley & Sons, Oxford"},{"key":"2466_CR37","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1086\/516781","volume":"44","author":"NB Halasa","year":"2007","unstructured":"Halasa NB, Shankar SM, Talbot TR et al (2007) Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 44:1428\u20131433. https:\/\/doi.org\/10.1086\/516781","journal-title":"Clin Infect Dis"},{"key":"2466_CR38","doi-asserted-by":"publisher","first-page":"232470962093430","DOI":"10.1177\/2324709620934303","volume":"8","author":"S Samrah","year":"2020","unstructured":"Samrah S, Sweidan A, Aleshawi A, Ayesh M (2020) Fusarium induced cellulitis in an immunocompetent patient with sickle cell disease: a case report. J Investig Med High Impact Case Rep 8:232470962093430. https:\/\/doi.org\/10.1177\/2324709620934303","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2466_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/BF01982190","volume":"13","author":"M Rabodonirina","year":"1994","unstructured":"Rabodonirina M, Piens MA, Monier MF et al (1994) Fusarium infections in immunocompromised patients: case reports and literature review. Eur J Clin Microbiol Infect Dis 13:152\u2013161. https:\/\/doi.org\/10.1007\/BF01982190","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2466_CR40","first-page":"1","volume-title":"Evidence-based psoriasis","author":"GW Kimmel","year":"2018","unstructured":"Kimmel GW, Lebwohl M (2018) Psoriasis: overview and diagnosis. In: Bhutani T, Liao W, Nakamura M (eds) Evidence-based psoriasis. Springer International Publishing, Cham, pp 1\u201316"},{"key":"2466_CR41","first-page":"s216","volume":"22","author":"A Menter","year":"2016","unstructured":"Menter A (2016) Psoriasis and psoriatic arthritis overview. Am J Manag Care 22:s216-224","journal-title":"Am J Manag Care"},{"key":"2466_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1034\/j.1600-0625.2000.009001001.x","volume":"9","author":"T Terui","year":"2000","unstructured":"Terui T, Ozawa M, Tagami H (2000) Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop: Neutrophils in T-cell-mediated immune dermatosis and psoriasis. Exp Dermatol 9:1\u201310. https:\/\/doi.org\/10.1034\/j.1600-0625.2000.009001001.x","journal-title":"Exp Dermatol"},{"key":"2466_CR43","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3389\/fimmu.2019.00746","volume":"10","author":"S Shao","year":"2019","unstructured":"Shao S, Fang H, Dang E et al (2019) Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4\/IL-36R crosstalk. Front Immunol 10:746. https:\/\/doi.org\/10.3389\/fimmu.2019.00746","journal-title":"Front Immunol"},{"key":"2466_CR44","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD et al (2018) Sickle cell disease. Nat Rev Dis Primer 4:18010. https:\/\/doi.org\/10.1038\/nrdp.2018.10","journal-title":"Nat Rev Dis Primer"},{"key":"2466_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2020.04.012","volume":"224","author":"JTC de Azevedo","year":"2020","unstructured":"de Azevedo JTC, Malmegrim KCR (2020) Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives. Immunol Lett 224:1\u201311. https:\/\/doi.org\/10.1016\/j.imlet.2020.04.012","journal-title":"Immunol Lett"},{"key":"2466_CR46","first-page":"93","volume":"103","author":"S Pulusani","year":"2019","unstructured":"Pulusani S, McMurray SL, Jensen K, Jones AV (2019) Psoriasis treatment in patients with sickle cell disease. Cutis 103:93\u201394","journal-title":"Cutis"},{"key":"2466_CR47","first-page":"611","volume":"84","author":"RB Francis","year":"1992","unstructured":"Francis RB, Haywood LJ (1992) Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 84:611\u2013615","journal-title":"J Natl Med Assoc"},{"key":"2466_CR48","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/archdermatol.2011.3362","volume":"148","author":"P Senet","year":"2012","unstructured":"Senet P, Combemale P, Debure C et al (2012) Malignancy and chronic leg ulcers: the value of systematic wound biopsies: a prospective, multicenter, cross-sectional study. Arch Dermatol 148:704\u2013708. https:\/\/doi.org\/10.1001\/archdermatol.2011.3362","journal-title":"Arch Dermatol"},{"key":"2466_CR49","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/01.ASW.0000383211.18782.2a","volume":"23","author":"ME Asuquo","year":"2010","unstructured":"Asuquo ME, Ikpeme IA, Ebughe G, Bassey EE (2010) Marjolin\u2019s ulcer: Sequelae of mismanaged chronic cutaneous ulcers. Adv Skin Wound Care 23:414\u2013416. https:\/\/doi.org\/10.1097\/01.ASW.0000383211.18782.2a","journal-title":"Adv Skin Wound Care"},{"key":"2466_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1341-9","author":"B Soutou","year":"2020","unstructured":"Soutou B, Senet P, Lionnet F et al (2020) Sickle cell disease induces resistance to cutaneous carcinogenesis. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-020-1341-9","journal-title":"Orphanet J Rare Dis"},{"key":"2466_CR51","doi-asserted-by":"publisher","first-page":"939","DOI":"10.7326\/0003-4819-148-12-200806170-00221","volume":"148","author":"S Lanzkron","year":"2008","unstructured":"Lanzkron S, Strouse JJ, Wilson R et al (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 148:939. https:\/\/doi.org\/10.7326\/0003-4819-148-12-200806170-00221","journal-title":"Ann Intern Med"},{"key":"2466_CR52","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1586\/17474086.2015.1078235","volume":"8","author":"GD Pule","year":"2015","unstructured":"Pule GD, Mowla S, Novitzky N et al (2015) A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Rev Hematol 8:669\u2013679. https:\/\/doi.org\/10.1586\/17474086.2015.1078235","journal-title":"Expert Rev Hematol"},{"key":"2466_CR53","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","volume":"289","author":"MH Steinberg","year":"2003","unstructured":"Steinberg MH, Barton F, Castro O et al (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289:1645\u20131651. https:\/\/doi.org\/10.1001\/jama.289.13.1645","journal-title":"JAMA"},{"key":"2466_CR54","first-page":"467","volume":"137","author":"B Chaine","year":"2001","unstructured":"Chaine B, Neonato M-G, Girot R, Aractingi S (2001) Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol 137:467\u2013470","journal-title":"Arch Dermatol"},{"key":"2466_CR55","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1182\/blood-2014-08-435768","volume":"124","author":"TE Wong","year":"2014","unstructured":"Wong TE, Brandow AM, Lim W, Lottenberg R (2014) Update on the use of hydroxyurea therapy in sickle cell disease. Blood 124:3850\u20133857. https:\/\/doi.org\/10.1182\/blood-2014-08-435768","journal-title":"Blood"},{"key":"2466_CR56","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cncr.26194","volume":"118","author":"R Latagliata","year":"2012","unstructured":"Latagliata R, Spadea A, Cedrone M et al (2012) Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer 118:404\u2013409. https:\/\/doi.org\/10.1002\/cncr.26194","journal-title":"Cancer"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02466-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-022-02466-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02466-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T11:08:03Z","timestamp":1681124883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-022-02466-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["2466"],"URL":"https:\/\/doi.org\/10.1007\/s00403-022-02466-5","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"2 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no financial disclosures, commercial associations, or any other conditions posing a conflict of interest to report for any of the above authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}